Carlson College of Veterinary Medicine

S. Mukherjee, Petrofsky, M., Yaraei, K., Bermudez, L. E., and Cangelosi, G. A., “The white morphotype of Mycobacterium avium-intracellulare is common in infected humans and virulent in infection models.”, The Journal of infectious diseases, vol. 184, no. 11, pp. 1480-4, 2001.

L. E. Bermudez, Petrofsky, M., and Stevens, P., “Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice.”, Immunology, vol. 94, no. 3, pp. 297-303, 1998.

L. E. Bermudez, Goodman, J., and Petrofsky, M., “Role of complement receptors in uptake of Mycobacterium avium by macrophages in vivo: evidence from studies using CD18-deficient mice.”, Infection and immunity, vol. 67, no. 9, pp. 4912-6, 1999.

L. E. Bermudez and Petrofsky, M., “Regulation of the expression of Mycobacterium avium complex proteins differs according to the environment within host cells.”, Immunology and cell biology, vol. 75, no. 1, pp. 35-40, 1997.

L. E. Bermudez, Martinelli, J., Petrofsky, M., Kolonoski, P., and Young, L. S., “Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model.”, The Journal of infectious diseases, vol. 169, no. 3, pp. 575-80, 1994.

M. Petrofsky and Bermudez, L. E., “Neutrophils from Mycobacterium avium-infected mice produce TNF-alpha, IL-12, and IL-1 beta and have a putative role in early host response.”, Clinical immunology (Orlando, Fla.), vol. 91, no. 3, pp. 354-8, 1999.

F. J. Sangari, Goodman, J., Petrofsky, M., Kolonoski, P., and Bermudez, L. E., “Mycobacterium avium invades the intestinal mucosa primarily by interacting with enterocytes.”, Infection and immunity, vol. 69, no. 3, pp. 1515-20, 2001.

S. Y. Kim, Goodman, J. R., Petrofsky, M., and Bermudez, L. E., “Mycobacterium avium infection of gut mucosa in mice associated with late inflammatory response and intestinal cell necrosis.”, Journal of medical microbiology, vol. 47, no. 8, pp. 725-31, 1998.

F. J. Sangari, Petrofsky, M., and Bermudez, L. E., “Mycobacterium avium infection of epithelial cells results in inhibition or delay in the release of interleukin-8 and RANTES.”, Infection and immunity, vol. 67, no. 10, pp. 5069-75, 1999.

N. Azouaou, Petrofsky, M., Young, L. S., and Bermudez, L. E., “Mycobacterium avium infection in mice is associated with time-related expression of Th1 and Th2 CD4+ T-lymphocyte response.”, Immunology, vol. 91, no. 3, pp. 414-20, 1997.

L. E. Bermudez, Wu, M., Petrofsky, M., and Young, L. S., “Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages.”, Infection and immunity, vol. 60, no. 10, pp. 4245-52, 1992.

L. E. Bermudez and Petrofsky, M., “Host defense against Mycobacterium avium does not have an absolute requirement for major histocompatibility complex class I-restricted T cells.”, Infection and immunity, vol. 67, no. 6, pp. 3108-11, 1999.

L. E. Bermudez, Petrofsky, M., and Goodman, J., “Exposure to low oxygen tension and increased osmolarity enhance the ability of Mycobacterium avium to enter intestinal epithelial (HT-29) cells.”, Infection and immunity, vol. 65, no. 9, pp. 3768-73, 1997.

L. E. Bermudez, Young, L. S., Martinelli, J., and Petrofsky, M., “Exposure to ethanol up-regulates the expression of Mycobacterium avium complex proteins associated with bacterial virulence.”, The Journal of infectious diseases, vol. 168, no. 4, pp. 961-8, 1993.

L. E. Bermudez, Petrofsky, M., and Shelton, K., “Epidermal growth factor-binding protein in Mycobacterium avium and Mycobacterium tuberculosis: a possible role in the mechanism of infection.”, Infection and immunity, vol. 64, no. 8, pp. 2917-22, 1996.

L. E. Bermudez, Petrofsky, M., Kolonoski, P., and Young, L. S., “Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy.”, Antimicrobial agents and chemotherapy, vol. 42, no. 1, pp. 180-3, 1998.

L. E. Bermudez, Petrofsky, M., Inderlied, C. B., and Young, L. S., “Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice.”, The Journal of antimicrobial chemotherapy, vol. 36, no. 4, pp. 641-6, 1995.

L. E. Bermudez, Nash, K. A., Petrofsky, M., Young, L. S., and Inderlied, C. B., “Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model.”, The Journal of infectious diseases, vol. 174, no. 6, pp. 1218-22, 1996.

L. E. Bermudez, Nash, K., Petrofsky, M., Young, L. S., and Inderlied, C. B., “Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice.”, Antimicrobial agents and chemotherapy, vol. 44, no. 10, pp. 2619-22, 2000.

L. E. Bermudez, Petrofsky, M., Wu, M., and Young, L. S., “Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice.”, The Journal of infectious diseases, vol. 178, no. 3, pp. 896-9, 1998.

L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., and Young, L. S., “Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice.”, Antimicrobial agents and chemotherapy, vol. 38, no. 12, pp. 2717-21, 1994.

L. E. Bermudez, Parker, A., and Petrofsky, M., “Apoptosis of Mycobacterium avium-infected macrophages is mediated by both tumour necrosis factor (TNF) and Fas, and involves the activation of caspases.”, Clinical and experimental immunology, vol. 116, no. 1, pp. 94-9, 1999.

L. E. Bermudez, Petrofsky, M., Kolonoski, P., and Young, L. S., “An animal model of Mycobacterium avium complex disseminated infection after colonization of the intestinal tract.”, The Journal of infectious diseases, vol. 165, no. 1, pp. 75-9, 1992.

L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., and Young, L. S., “Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.”, Antimicrobial agents and chemotherapy, vol. 45, no. 1, pp. 217-22, 2001.